Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CC chemokine receptor 4 (CCR4), also known as CD194, is a G protein-coupled receptor (GPCR) primarily involved in immune cell trafficking. It binds to chemokines CCL17 and CCL22, influencing inflammatory responses and tumor microenvironments. CCR4 expression is found on various immune cells, including Th2 cells and regulatory T cells. It is implicated in autoimmune diseases, allergic conditions, cancer metastasis, and neuropathic pain. Mogamulizumab, a monoclonal antibody targeting CCR4, is used in CTCL treatment.
Humanized monoclonal antibody targeting CCR4
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CC chemokine receptor 4 (CCR4).